HIV drug bridge for kids: ensuring treatment continuity
NCT ID NCT03016533
First seen Feb 05, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study gave children and teens with HIV continued access to the drug dolutegravir after they finished earlier clinical trials. About 100 participants who were already doing well on the medication received it every 12 weeks until local approved versions became available. The goal was to keep them on effective treatment without interruption.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Los Angeles, California, 90095, United States
-
GSK Investigational Site
Fort Lauderdale, Florida, 33316, United States
-
GSK Investigational Site
Memphis, Tennessee, 38105-3678, United States
-
GSK Investigational Site
Gaborone, Botswana
-
GSK Investigational Site
Belo Horizonte, 30130-100, Brazil
-
GSK Investigational Site
Nova Iguaçu, 26030-380, Brazil
-
GSK Investigational Site
RibeirAo PretoSP, 14048-900, Brazil
-
GSK Investigational Site
Rio de Janeiro, 21941-612, Brazil
-
GSK Investigational Site
Cape Town, 7505, South Africa
-
GSK Investigational Site
Johannesburg, 2001, South Africa
-
GSK Investigational Site
Soweto, 1862, South Africa
-
GSK Investigational Site
Umlazi, 4066, South Africa
-
GSK Investigational Site
Moshi, 3010, Tanzania
-
GSK Investigational Site
Bangkok, 10700, Thailand
-
GSK Investigational Site
Chiang Mai, 50200, Thailand
-
GSK Investigational Site
Chiang Rai, 57000, Thailand
-
GSK Investigational Site
Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.